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Abstract
Neuroinflammation and neurodegeneration often result from the
aberrant deposition of aggregated host proteins, including
amyloid-b, a-synuclein, and prions, that can activate inflamma-
somes. Inflammasomes function as intracellular sensors of both
microbial pathogens and foreign as well as host-derived danger
signals. Upon activation, they induce an innate immune response
by secreting the inflammatory cytokines interleukin (IL)-1b and
IL-18, and additionally by inducing pyroptosis, a lytic cell death
mode that releases additional inflammatory mediators. Microglia
are the prominent innate immune cells in the brain for inflamma-
some activation. However, additional CNS-resident cell types includ-
ing astrocytes and neurons, as well as infiltrating myeloid cells from
the periphery, express and activate inflammasomes. In this review,
we will discuss current understanding of the role of inflamma-
somes in common degenerative diseases of the brain and highlight
inflammasome-targeted strategies that may potentially treat
these diseases.
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Introduction
The innate immune system is a rapid and coordinated cellular
defense response that aims to eliminate the threat posed by both
sterile and infectious insults. Recognition of these pathogenic agents
is mediated by pattern recognition receptors (PRRs) that sense
pathogen-associated molecular patterns (PAMPs) and host- or envi-
ronment-derived danger-associated molecular patterns (DAMPs). In
the central nervous system (CNS), these PRRs are primarily
expressed by microglia, astrocytes, and macrophages, but also
oligodendrocytes, neurons, and endothelial cells express a repertoire
of PRRs (Lampron et al, 2013; Walsh et al, 2014). PRRs can either
be membrane-bound, as is the case for the Toll-like receptors
(TLRs), to sense signals in the extracellular environment or in the
endosome, or they can be intracellular, as with the nucleotide-
binding domain and leucine-rich repeat-containing receptors (NLRs)
and AIM2-like receptors (ALRs). An important subgroup of cytosolic
PRRs that includes members of the NLR and ALR families as well as
the tripartite motif (TRIM) family member pyrin critically contri-
butes to the innate immune response by assembling so-called
“inflammasomes”.
General concepts of inflammasome biology
Inflammasomes are cytosolic multiprotein complexes which upon
assembly activate the pro-inflammatory caspase-1 (see Glossary)
that is responsible for the maturation and secretion of the inflamma-
tory cytokines IL-1b and IL-18, and additionally induce pyroptosis
(Lamkanfi & Dixit, 2014; Broz & Dixit, 2016). Briefly, inflamma-
some-inducing stimuli trigger the oligomerization of PRR proteins
and the recruitment of pre-existing procaspase-1 zymogens into the
complex, leading to their proximity-induced autoactivation to gener-
ate active caspase-1. Consequently, caspase-1 will cleave the biolog-
ically inactive pro-peptides pro-IL-1b and pro-IL-18 into mature
cytokines which are then secreted by the cell. Next to its role in the
maturation of pro-IL-1b and pro-IL-18, caspase-1 can also induce a
pro-inflammatory form of cell death, pyroptosis, that features early
plasma membrane rupture, thereby releasing the soluble intracellu-
lar fraction that fuels the inflammatory response (Lamkanfi & Dixit,
2012, 2014). Central in this process is the executioner protein
gasdermin D (GSDMD)—a substrate of murine caspase-1 and
caspase-11, and human caspase-1, caspase-4, and caspase-5—the
amino-terminal domain of which upon cleavage oligomerizes and
perforates the plasma membrane to induce cell swelling and osmotic
lysis (Shi et al, 2017) (Fig 1).
One way to classify inflammasome complexes is based on the
receptor that initiates signaling (Lamkanfi & Dixit, 2012). The core
inflammasome components consist of the cytosolic NLR, ALR, and
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pyrin receptors, the adaptor apoptosis-associated speck-like protein
containing a caspase recruitment domain (ASC) and procaspase-1.
ASC is composed of a pyrin domain (PYD) and a caspase recruit-
ment domain (CARD) and functions as an adaptor that links the
PYD of the NLR or pyrin and the CARD of procaspase-1 (Fig 2).
Some inflammasomes, such as NLRC4 and NLRP1b, do not require
ASC and may directly recruit procaspase-1 through their respective
CARDs, although under wild-type conditions ASC does contribute
to optimal caspase-1 activation and efficient secretion of IL-1b and
IL-18 (Broz et al, 2010; Guey et al, 2014; Van Opdenbosch et al,
2014). Assembly and activation of inflammasomes requires detec-
tion of specific signals: Murine Nlrp1b responds to Bacillus
anthracis lethal toxin (LeTx) (Boyden & Dietrich, 2006); NLRC4
detects intracellular flagellin and components of type III secretion
systems (T3SS) of bacterial pathogens (Franchi et al, 2006; Miao
et al, 2006, 2010); AIM2 physically binds cytosolic double-
stranded DNA (dsDNA) (Hornung et al, 2009); and pyrin indirectly
responds to toxins that covalently inactivate the small GTPase
RhoA (Xu et al, 2014). NLRP3, the most widely studied inflamma-
some, responds to a broad spectrum of activating stimuli that
includes a suite of bacterial, fungal, and viral PAMPs, DAMPs
such as ATP and uric acid crystals, and crystalline and aggregated
substances such as asbestos, silica, and amyloid-b fibrils
(Lamkanfi & Dixit, 2012). NLRP3 activation is unique in the sense
that it involves a two-step process. A first signal, or priming
signal, results in the NF-jB-dependent transcriptional upregulation
of NLRP3 and pro-IL-1b, but also controls post-translational modi-
fications of NLRP3 as highlighted by the mapped ubiquitin and
phosphorylation sites on NLRP3 (Yang et al, 2017). This is
followed by a second “activation” signal that induces the
oligomerization and activation of the NLRP3 inflammasome
(Fig 1). Besides canonical NLRP3 inflammasome signaling, the
non-canonical NLRP3 inflammasome pathway involves activation
of caspase-11 (or its human orthologs caspase-4 and caspase-5) by
Glossary
Blood–brain barrier (BBB)
a physiological barrier between the blood and the CNS parenchyma. The
BBB is formed by endothelial cells that are joined by complex tight
junctions and coated by a basement membrane and an additional
membrane of astrocytic end-feet, known as the glia limitans.
Caspases
a family of cysteine-dependent aspartate specific proteases that play
a central role in inflammation and programmed cell death.
Cerebrospinal fluid (CSF)
contained in the ventricles of the brain and the cranial and spinal
subarachnoid spaces. It provides a mean for transporting different
molecules, including cytokines, neurotransmitters, and hormones, but
also resides innate immune cells.
CNS macrophages
non-parenchymal macrophages of the CNS that are located in
meninges, choroid plexus, and perivascular spaces.
Creutzfeldt–Jakob disease
fatal degenerative prion disease that can be sporadic, hereditary, or
acquired. The acquired form of the disease is caused by exposure to
the misfolded scrapie form of the PrP protein.
Cuprizone-induced demyelination
an experimental model to study local demyelination of the corpus
callosum, which is induced by the administration of the copper
chelator cuprizone (bis(cyclohexanone)oxaldihydrazone) to the food of
mice during 5 weeks.
Dopaminergic neurons
the main dopamine-producing cells of the CNS and essential for
controlling key functions of the brain, including voluntary movement,
reward processing, mood, and working memory.
Encephalomyelitis
general term to describe inflammation in the brain or spinal cord.
Autoimmune encephalomyelitis is caused by an abnormal immune
response to a self-antigen.
Experimental autoimmune encephalomyelitis (EAE)
the main rodent model of MS. EAE is actively induced by peripheral
immunization with myelin-specific proteins or peptides in
combination with an adjuvant, or passively by transfer of
encephalitogenic T cells.
Familial Mediterranean Fever
the most common monogenic autoinflammatory disease and is
characterized by periodic fevers with childhood onset, and frequently
associated with serositis and joint pain. It predominantly affects
Mediterranean populations.
Grand-mal seizures
or tonic-clonic seizures: seizures that are characterized by the loss
of consciousness and violent muscle contractions. This seizure
comes in two phases: a tonic phase followed by a clonic phase.
The brief tonic phase features loss of consciousness and muscle
stiffening, while in the clonic phase the muscles go into rhythmic
contractions.
Induced pluripotent stem cells (iPSCs)
generated by genetic reprogramming of adult somatic cells. The
advantage over other types of stem cells is that they are not derived
from a human embryo.
Ischemic infarct
an infarct caused by the interruption of the blood flow in the brain
due to occlusion of a cerebral vessel.
Middle cerebral artery occlusion
experimental stroke model that involves the permanent or transient
occlusion of the middle cerebral artery. The middle cerebral artery is
one of the three arteries that supply blood to the cerebrum. In the
“filament model”, a suture filament is (transiently) introduced into the
internal carotid artery and forwarded until the tip occludes the
middle cerebral artery.
Neonatal-onset multisystem inflammatory disease (NOMID)
or chronic infantile neurologic cutaneous and articular (CINCA):
the most severe cryopyrin-associated periodic syndrome (CAPS).
NOMID is characterized by neonatal-onset skin lesions, chronic
aseptic meningitis, and recurrent fever along with joint symptoms.
Sepsis
a life-threatening systemic inflammatory response syndrome (SIRS)
caused by the body’s response to an infection.
Spatial memory
an important cognitive function that allows us to recall three-
dimensional objects or places.
Steatohepatitis
a type of fatty liver disease and is characterized by the accumulation
of lipids and the infiltration of inflammatory cells in the hepatic
parenchyma.
Striata
dopamine neurons from the substantia nigra pars compacta project
to the caudate and the putamen of the basal ganglia, together
referred to as the striatum.
Substantia nigra pars compacta
structure in the brainstem that contains most of the dopamine-
producing neurons.
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cytosolic LPS, and the induction of pyroptosis through the cleav-
age of GSDMD and the release of high mobility group box 1
protein (HMGB1) and IL-1a (Lamkanfi & Dixit, 2014; Shi et al,
2017). Apart from AIM2 and the NAIP/NLRC4 complexes, the
common secondary messengers or physical ligands that bind and
trigger inflammasome assembly await discovery.
Inflammasomes and the central nervous system
IL-1b and IL-18 have important functions in the CNS, and many cell
types in the brain express their cognate receptors that initiate
inflammatory signaling cascades that may contribute to neuronal
injury and cell death (Allan et al, 2005; Alboni et al, 2010). Hence,
increased levels of IL-1b and IL-18 are often observed upon CNS
infection, brain injury, and neurodegenerative diseases (Heneka
et al, 2014, 2018). IL-1b and IL-18 are also important for physiologi-
cal functions in the CNS and have been shown to participate to
processes of cognition, learning, and memory (Tsai, 2017). Pyropto-
sis additionally contributes to inflammasome-driven pathology
through the release of other inflammatory mediators and DAMPs.
Apoptosis and necroptosis are additional cell death modes that have
been shown to promote neuroinflammation and neuronal degenera-
tion in several neurodegenerative pathologies, including multiple
sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, and
Alzheimer’s disease (Zhang et al, 2017; Yuan et al, 2019).
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Figure 1. Inflammasome activation and signaling.
Inflammasomes assemble in a stimulus-specific manner. Different DAMPs and PAMPs are able to induce NLRP3, while NLRP1b responds to Bacillus anthracis lethal toxin,
NLRC4 recognizes bacterial flagellin and/or the type III secretion system of bacterial pathogens, AIM2 is specifically activated by dsDNA, and pyrin recognizes the inactivation
of RhoA by toxins and effector proteins. Activation of the NLRP3 inflammasome involves a two-step mechanism. The priming signal is detected by membrane-bound PRRs,
including TLRs and C-type lectin receptors (CLRs) and induces NF-jB-dependent transcription of NLRP3 and pro-IL-1b precursor protein, and controls post-translational
modifications that license NLRP3 activation. The second activation signal is necessary for inflammasome formation, depending on the oligomerization and subsequent
activation of procaspase-1. Active caspase-1 then cleaves pro-IL-1b and pro-IL-18 to their mature forms IL-1b and IL-18which get secreted. In addition, caspase-1 can cleave
gasdermin D, releasing its N-terminal fragment which translocates to the plasma membrane inducing pore formation and pyroptotic cell death. In contrast to NLRP3, other
inflammasome receptors do not need this initial priming signal to induce inflammasome activation and cytokine release.
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Although inflammasome signaling in the CNS is mainly attrib-
uted to microglia, the key innate immune cells of the brain, expres-
sion of inflammasome components has also been reported in other
cell types of the CNS, including neurons (Kaushal et al, 2015),
astrocytes (Freeman et al, 2017), perivascular CNS macrophages
(Kawana et al, 2013), oligodendrocytes (Mckenzie et al, 2018), and
endothelial cells (Gong et al, 2018) (Fig 3). However, current under-
standing of inflammasome activation in microglia and its role in
CNS inflammation and disease is still fragmentary and primarily
based on in vitro studies with primary microglia and microglial cell
lines, and in vivo studies with transgenic knockout mice that lack
expression of specific inflammasome components throughout the
body. More appropriate research tools that allow CNS-specific
inflammasome targeting are needed to investigate the relative
contribution of local inflammasome signaling in specific brain cell
types to overall CNS pathology. Furthermore, evidence for
inflammasome activation in patients with neurodegenerative disease
often relies on detection of higher IL-1b transcript levels and/or
increased gene and protein expression of inflammasome compo-
nents. However, increased expression levels of these NF-jB respon-
sive genes are largely indicative of an ongoing inflammatory
response rather than direct support for inflammasome engagement.
We here review the current knowledge on the relevance of
inflammasome activation for the most common neurodegenerative
pathologies (Fig 3 and Table 1) and highlight emerging strategies
for the treatment of inflammasome-driven diseases. Although
inflammasome activation is also central to the pathology of many
CNS infectious diseases, such as Zika, HIV, and West Nile virus,
and bacterial infections that induce meningitis (Walsh et al, 2014;
Mamik & Power, 2017; Heneka et al, 2018), these conditions are
outside the scope of this review.
Inflammasome activation in multiple sclerosis and
experimental autoimmune encephalomyelitis
Multiple sclerosis (MS) is the most common chronic inflammatory
disease of the CNS. MS is characterized by a compromised blood–
brain barrier (BBB) that leads to immune cell infiltration from the
periphery and local microglia and astrocyte activation, which
together promote inflammation, demyelination, and neurodegenera-
tion (Baecher-Allan et al, 2018). Experimental autoimmune
encephalomyelitis (EAE) is a widely used rodent model of MS
(Ransohoff, 2012), and both IL-1b and IL-18 were shown to critically
contribute to EAE (Sutton et al, 2006; Gris et al, 2010; Le´vesque
et al, 2016). Most studies on the involvement of inflammasomes in
MS have focused on the peripheral immune response that is shaped
by lymphocytes and macrophages that enter the CNS during MS
pathology. Caspase-1, IL-18, and IL-1b are upregulated in peripheral
blood mononuclear cells (PBMCs) and cerebrospinal fluid (CSF) of
MS patients, as are levels of the NLRP3 inflammasome-activating
DAMPs ATP and uric acid (Inoue & Shinohara, 2013; Mamik &
Power, 2017). Moreover, caspase-1 expression was shown to be
elevated in acute and chronic demyelinating lesions (Voet et al,
2018), and caspase-1 and ASC have recently been proposed as
candidate biomarkers for MS onset (Keane et al, 2018).
The role of the NLRP3 inflammasome in EAE-associated T-cell
priming and trafficking into the CNS is supported by the analysis
of NLRP3, caspase-1, and ASC knockout mice (Furlan et al, 1999;
Gris et al, 2010; Inoue et al, 2012a). Moreover, the pharmacologi-
cal NLRP3 inflammasome inhibitor MCC950/CRID3 was shown to
suppress IL-1b production and attenuate EAE severity in wild-type
mice (Coll et al, 2015). Similarly, pharmacological blockade of
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Figure 2. Domain structure of inflammasomes.
A subset of NLRs and ALRs can trigger the formation of inflammasomes. NLR
family members have a nucleotide-binding and oligomerization domain
(NACHT/NBD), as well as leucine-rich repeat (LRR) motifs, typically located in the
center and carboxy terminus of the NLR proteins, respectively. The NACHT motif
is usually flanked by an additional amino-terminal domain, either CARD or PYD,
and these domains are used for further sub-classification of inflammasomes.
These domains allow the recruitment of adaptor and effector proteins to the
inflammasome signaling complex. The NLR gene family consists of 22 human
members and 34 murine members, many of which the function is not always
clear (Lamkanfi & Dixit, 2012; Broz & Dixit, 2016). In addition to the NLR-
containing inflammasomes, the ALR family member AIM2 can also assemble an
inflammasome complex. AIM2 is characterized by an amino-terminal PYD
domain and one or two DNA-binding HIN200 domains (Hornung et al, 2009).
Pyrin, also known as TRIM20, features a PYD domain, two B-boxes, and a coiled-
coil domain, whereas the human pyrin also has an additional C-terminal B30.2
domain. ASC is the critical adaptor protein for many inflammasome complexes
and is composed of CARD and PYD domains, the latter being necessary for
homotypic interaction with a PYD-containing inflammasome sensor (NLRP3,
AIM2). Procaspase-1 features a CARD domain, in addition to its caspase domain,
and homotypic CARD interactions result in direct or indirect (via ASC)
recruitment of procaspase-1 to the inflammasome complex. Inflammasome
activation involves ASC and procaspase-1 recruitment, resulting in ASC
oligomerization into a macromolecular aggregate, known as an ASC speck (Broz
& Dixit, 2016).
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caspase protease activity with Z-Val-Ala-DL-Asp-fluoromethylke-
tone or the inflammatory caspase prodrug VX-765 reduced EAE
symptoms in mice (Furlan et al, 1999; Mckenzie et al, 2018).
Interestingly, IFNb, the first line treatment for MS, is only effective
in an NLRP3 inflammasome-dependent EAE subtype, whereas
NLRP3-independent EAE could not be reversed by IFN-b therapy
(Inoue et al, 2012b, 2016). We recently provided direct genetic
evidence for the relevance of inflammasome signaling in microglia
and border-associated macrophages during EAE (Voet et al, 2018).
The anti-inflammatory protein A20 has been shown to negatively
regulate NLRP3 inflammasome activation (Vande Walle et al,
2014), and deletion of A20 in microglia and CNS macrophages
exacerbated EAE in mice due to NLRP3 hyperactivation that
resulted in increased IL-1b secretion and CNS inflammation (Voet
et al, 2018). CNS-intrinsic inflammasome activation was further
reported in another study that showed caspase-1- and GSDMD-
mediated pyroptosis in microglia, as well as in myelin-forming
oligodendrocytes in the CNS of MS patients and EAE mice
(Mckenzie et al, 2018).
The relevance of the NLRP3 inflammasome to MS has also been
demonstrated in the model of cuprizone-induced demyelination, in
which NLRP3-deficient mice presented delayed demyelination,
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Figure 3. Inflammasome activation in neurodegenerative disease.
Inflammasomes can be activated in the CNS in response to acute injury (traumatic brain injury and stroke), autoimmune-mediated injury (multiple sclerosis), and
accumulation of misfolded or aggregated proteins in the brain (Alzheimer’s disease, amyotrophic lateral sclerosis, Parkinson’s disease, and prion disease). Inflammasome
activation has been demonstrated in CNS-resident cell types, including microglia, astrocytes, and neurons, but also in CNS-infiltrating cells, such as in infiltrating
macrophages. Although most research on neurodegenerative diseases has focused on the importance of the NLRP3 inflammasome, also other inflammasome types can be
activated in the brain and have been demonstrated in neurodegenerative disorders. Overall, inflammasome activation results in caspase-1-mediated cleavage of pro-IL-1b
and pro-IL-18, and the subsequent release of themature cytokines. High levels of IL-1b and IL-18 can be detected inmany neurodegenerative conditions and are considered to
be crucial for the establishment of a chronic inflammatory environment, leading to neuronal dysfunction and eventually neurodegeneration.
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oligodendrocyte loss, and neuroinflammation (Jha et al, 2010).
Additional support was provided by similar observations in caspase-
1 and IL-18 knockout mice, which unlike IL-1b knockout mice
showed protection (Jha et al, 2010). Moreover, IL-1b and IL-18 had
a differential effect on the process of remyelination after cuprizone
treatment, demonstrating a delay in remyelination in IL-1b knockout
mice, whereas accelerated remyelination was seen in IL-18 knock-
outs (Jha et al, 2010).
Inflammasome activation in stroke
Neuroinflammation plays a crucial pathological role in stroke, and
IL-1b has been identified as a key cytokine in stroke pathology. So
far, four distinct inflammasomes have been implicated in stroke,
viz. NLRP1, NLRP3, NLRC4, and AIM2 (Barrington et al, 2017).
Additionally, early studies implicated caspase-11 in middle cerebral
artery occlusion (MCAO), a mouse model of stroke (Kang et al,
Table 1. Overview of the described neurodegenerative disease models.
Disease model Description
Multiple sclerosis
EAE EAE is actively induced by peripheral immunization with myelin-specific proteins or peptides in combination with an
adjuvant, or passively by transfer of encephalitogenic T cells
Cuprizone Administration of the copper chelator cuprizone will induce local demyelination of the corpus callosum
Stroke
Permanent MCAO Permanent occlusion of the middle cerebral artery is obtained using an intraluminal suture
Transient MCAO Intraluminal suture MCAO utilizes a suture inserted into the middle cerebral artery to interrupt the blood flow for a specific
duration and is afterward removed. Embolic stroke MCAO uses an autologous blood clot injected into the MCA to occlude
the vessel
Intracerebral hemorrhage (ICH) Stroke condition provoked by injection of autologous arterial blood into the basal ganglia
TBI and SCI
Controlled cortical impact (CCI) A mechanical model of traumatic brain injury. Following craniotomy, the CCI device mechanically transfers energy onto the
dura mater damaging the cortex, and sometimes the subcortical structures
Impact acceleration model The exposed skull is covered with a steel disk and a weight is dropped onto the steel disk
Contusion model of spinal cord
injury
A transient force is applied by either an electromagnetic device or a weight-drop to displace and damage the spinal cord
Alzheimer disease
APP/PS1 Mouse model expressing human APP695 with the Swedish double mutation (K670N/M671L) and a mutant human presenilin
1 (PS1-dE9)
3xTgAD Mouse model expressing human APP695 with the Swedish double mutation (K670N/M671L), human PS1 with the M146V
mutation, and human Tau with the P301L mutation
Tg2567 Mouse model expressing human APP695 with the Swedish double mutation (K670N/M671L) at the b-secretase cleavage site
5xFAD Mouse model expressing human APP and PSEN1 transgenes with a total of five AD-linked mutations: the Swedish (K670N/
M671L), Florida (I716V), and London (V717I) mutations in APP, and M146L and L286V mutations in PSEN1
Amyotrophic lateral sclerosis
TgSOD1-G93A Mouse model expressing a G93A mutant form of human SOD1
hSOD1 G37R Mouse model expressing a G37R mutant form of human SOD1
hSOD1 G85R Mouse model expressing a G85R mutant form of human SOD1
Parkinson disease
A53T Mouse model expressing the mutant human A53T alpha-synuclein.
LPS-induced PD Injection of LPS in the left substantia nigra pars compacta
6-hydroxydopamine-induced PD Injection of 6-hydroxydopamine in the medial forebrain bundle
MPTP-induced PD Intraperitoneal injection of MPTP five times at 2-h intervals
Prion disease
Scrapie-infected Intracerebral infections with brain homogenate of scrapie strain 139A-infected mice or intracerebral injection with RML6
(passage 6 of Rocky Mountain Laboratory strain mouse-adapted scrapie prions)
Tg(CJD) Mouse model expressing a misfolded mutant PrP (D177N/V128)
Huntington disease
R6/2 Transgenic mice expressing exon 1 of human huntingtin with expanded CAG/polyglutamine repeat
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2000). Expression levels of NLRP3 and NLRP1, as well as cleavage
products of caspase-1, IL-1b, and IL-18, were shown to be elevated
in postmortem brain tissue of stroke patients (Fann et al, 2013).
Studies with pharmacological inhibitors of inflammatory caspases
and analysis of caspase-1-deficient mice—that were later shown to
also lack caspase-11 expression (Kayagaki et al, 2011)—showed
protection in experimental models of stroke (Friedlander et al, 1997;
Hara et al, 1997; Schielke et al, 1998; Rabuffetti et al, 2000; Ross
et al, 2007). In agreement, mice deficient in both IL-1a and IL-1b
exhibited dramatically reduced ischemic infarct volumes in transient
MCAO (Boutin et al, 2001), whereas IL-18-deficient mice did not
show protection in this model (Wheeler et al, 2003). NLRP3 defi-
ciency in mice, treatment with the NLRP3 inflammasome inhibitor
MCC950/CRID3, and intracerebroventricular injection of NLRP3
siRNAs all ameliorated clinical outcomes in experimental models of
stroke (Ma et al, 2014; Yang et al, 2014; Yuan et al, 2015; Ismael
et al, 2018b). Also, NLRC4- and AIM2-deficient mice were shown to
have significantly smaller infarct volumes compared to wild-type
mice subjected to tMCAO, with was associated with strongly
reduced microglia cell activation and leukocyte recruitment to the
infarct site (Denes et al, 2015). Finally, an expression analysis in the
peri-infarct zone of transient MCAO rats revealed elevated levels of
the inflammasome components NLRP1, NLRP3, AIM2, NLRC4, and
ASC (Lammerding et al, 2016), consistent with the potential activa-
tion of multiple inflammasomes in stroke.
Inflammasome activation in traumatic brain and spinal
cord injury
Patients with traumatic brain injury (TBI) have significantly higher
levels of inflammasome markers in their CSF, including ASC,
caspase-1, NLRP1, and NLRP3 (Adamczak et al, 2012; Wallisch
et al, 2017). However, NLRP1b and ASC knockout mice did not
show any improvement in motor recovery or lesion volume in
conditions of TBI, compared to control mice, although their levels of
IL-1b were reduced (Brickler et al, 2016). NLRP3 expression localiz-
ing to neurons, microglia, and astrocytes was also detected in exper-
imental TBI (Liu et al, 2013a), and NLRP3-deficient mice as well as
pharmacological blockade of NLRP3 activation were shown to
improve recovery from TBI (Irrera et al, 2017). Treatment with IL-
1b neutralizing antibodies also was shown to improve the cognitive
outcome following TBI (Clausen et al, 2009). In contrast to IL-1b
levels, which rapidly increase after TBI, IL-18 levels gradually
increase over several days, suggesting that IL-1b may be involved in
the early phase of TBI, while IL-18 may contribute to pathogenesis
at later phases of the disease. In agreement, IL-18 inhibition resulted
in improved neurologic recovery after 7 days with little effect on the
early response being observed immediately after injury (Yatsiv et al,
2002).
Similar to TBI, spinal cord injury (SCI) induced higher levels of
NLRP1, ASC, caspase-1, IL-1b, and IL-18 in mice, and therapeutic
neutralization of ASC was proposed to result in tissue sparing and
functional improvement due to reduced inflammasome activation in
neurons (de Rivero Vaccari et al, 2008). Furthermore, expression of
heme oxygenase-1 was shown to suppress NLRP1 inflammasome
activation and neuronal cell death, and lead to improved functional
recovery after SCI (Lin et al, 2016). Also, enhanced NLRP3
expression can be demonstrated in SCI, predominantly in neurons,
but also in microglia and astrocytes (Zendedel et al, 2016).
Inflammasome activation in Alzheimer’s disease
Alzheimer’s disease (AD) is the most common age-related neurode-
generative disorder and is characterized by progressive memory
deficits and cognitive impairment (Sala Frigerio & De Strooper,
2016). AD pathology is dominantly explained by the amyloid
hypothesis, which suggests that the increasing extracellular deposi-
tion of misfolded amyloid-beta (Ab) is the primary cause of the
disease. Although there is overwhelming evidence for a pathogenic
role for Ab in AD, neuroinflammation is increasingly regarded as
another key component that actively contributes to AD pathology
(De Strooper & Karran, 2016; Sala Frigerio & De Strooper, 2016).
Neuroinflammation in AD is primarily driven by the CNS-resident
microglia population (Sarlus & Heneka, 2017; Shi & Holtzman,
2018). Although it is recognized that microglia may exert benign
and reparative activities in AD through the phagocytic removal of
Ab deposits, the accumulation of Ab may also prime microglial cells
and promote their activation and production of inflammatory medi-
ators. Moreover, upon Ab accumulation, microglial cells may
become progressively impaired in their ability to phagocytose Ab
(Sarlus & Heneka, 2017; Shi & Holtzman, 2018). Furthermore, a
microglial inflammatory state would also impact on other CNS-resi-
dent cells and result in synaptic dysfunction and neuronal damage.
Many recent studies have implicated inflammasomes in the
development of AD. Elevated expression of IL-1b has been reported
in microglia that surround Ab plaques of AD patients (Griffin et al,
1989; Simard et al, 2006). Additionally, gene expression analysis of
cultured PBMCs from AD patients revealed higher expression of
NLRP3, ASC, caspase-1, and caspase-5 as well as the cytokines IL-
1b and IL-18 (Saresella et al, 2016). The expression levels of NLRC4
and ASC were also found significantly elevated in brain samples of
a subgroup of sporadic AD patients (Liu & Chan, 2014). Finally,
genetic variants of NLRP1 have been associated with AD risk
(Pontillo et al, 2012), and the amount of NLRP1 immunopositive
neurons was strongly increased in AD brain (Kaushal et al, 2015).
In vitro studies have shown that fibrillar Ab activates the
NLRP3 inflammasome when phagocytosed by microglia, leading to
activation of caspase-1 and release of IL-1b (Halle et al, 2008).
NLRP3 inflammasome activation has also been documented in vivo
in the transgenic APP/PS1 mouse model of AD, and deficiency in
NLRP3 significantly ameliorated spatial memory deficits and hyper-
active behavior in these mice, which was associated with reduced
hippocampal and cortical Ab deposition, smaller plaque volumes,
decreased levels of pro-inflammatory cytokines, and improved
microglial phagocytic ability (Heneka et al, 2013). Similar results
were obtained in APP/PS1 mice that were deficient in caspase-1
(Heneka et al, 2013). Inhibition of the NLRP3 inflammasome by
MCC950/CRID3 also promoted amyloid-b clearance and amelio-
rated cognitive function in APP/PS1 mice (Dempsey et al, 2017).
Indirect inhibition of NLRP3 inflammasome activation by clinically
approved fenamate non-steroidal anti-inflammatory drugs that
target cyclooxygenase enzymes and volume-regulated anion chan-
nels (VRAC) also was shown to suppress microglia-mediated
neuroinflammation and memory loss in 3×TgAD mice (Daniels
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et al, 2016). Finally, pharmacological inhibition of caspase-1 activ-
ity by VX-765 reduced amyloid-b accumulation, brain inflamma-
tion, and cognitive impairment (Flores et al, 2018). Collectively,
these findings suggest that misfolded Ab activates the microglial
NLRP3 inflammasome, which triggers the release of pro-inflamma-
tory factors that perpetrate a chronic neuroinflammatory environ-
ment and promote AD pathology. In addition, NLRP3
inflammasome activity also results in the extracellular release of
micrometer-sized ASC particles that may function as danger signals
and alert surrounding macrophages (Baroja-Mazo et al, 2014).
These ASC specks were shown to physically bind to Ab to seed
and spread Ab pathology in a prion-like manner by promoting
misfolded protein aggregation and plaque formation in the APP/
PS1 AD model (Venegas et al, 2017).
A pathogenic role for IL-1b in AD has been demonstrated in mice
with a deficiency in IL-1 receptor antagonist (IL-1ra), which resulted
in increased vulnerability to intracerebroventricular injection with
human oligomeric Ab1–42 (Craft et al, 2005). Another study
showed that IL-1b injection in the cerebral hemisphere increases
Ab-APP protein levels in wild-type mice (Sheng et al, 1996). In
contrast, sustained hippocampal IL-1b overexpression in APP/PS1
mice was shown to reduce plaque pathology, an observation that
might be explained by the increased phagocytic activity of microglia
and macrophages (Shaftel et al, 2007). Similar observations were
done in 3xTgAD mice, but tau phosphorylation was also increased
in these mice, demonstrating the complex role of IL-1 signaling in
AD (Ghosh et al, 2013). IL-1R1 deficiency in mice had no effect on
Ab deposition in Tg2567 AD mice (Das et al, 2006). Similarly, IL-18
deletion did not confer a protective effect in APP/PS1 mice (Tzeng
et al, 2018). However, these mice were shown to be highly suscepti-
ble to grand-mal seizures and exhibited increased excitatory synap-
tic proteins and dendritic spine density, an imbalance which leads
to a higher basal excitatory synaptic transmission (Tzeng et al,
2018). Therefore, IL-18 may have an unexpected role in controlling
neuronal activity.
Although the focus has been on the role of NLRP3 in AD, the role
of other inflammasomes has also been characterized in the context
of AD. The AIM2 inflammasome was shown to increase Ab deposi-
tion, microglia activation, and cytokine production, but does not
affect behavior or memory in transgenic 5xFAD mice (Wu et al,
2017). NLRP1 knockdown in APP/PS1 mice was shown to result in
significantly reduced neuronal pyroptosis and to rescue cognitive
impairments (Tan et al, 2014). Finally, the NLRC4 inflammasome
was shown to enhance neuronal Ab levels through activated pro-
inflammatory astrocytes (Liu & Chan, 2014).
Inflammasome activation in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative
disease that is caused by the progressive loss of upper and lower
motor neurons and leads to muscle weakness and wasting (Taylor
et al, 2016). Twenty percent of familial ALS cases are caused by
mutations in the gene that encodes superoxide dismutase 1 (SOD1),
and many experimental models of ALS rely on expression of mutant
SOD1. Deficiency in caspase-1 and IL-1b, as well as treatment with
the recombinant IL-1 receptor antagonist anakinra, all significantly
extended the lifespan of mutant SOD1 transgenic animals (Meissner
et al, 2010). Consistently, the expression of NLRP3, NLRC4, AIM2,
and caspase-1 activation has been demonstrated in neural tissue of
mutant SOD1 transgenic animals (Pasinelli et al, 1998; Johann et al,
2015; Gugliandolo et al, 2018), and mutant SOD1 was shown to
activate caspase-1 and IL-1b in microglia (Meissner et al, 2010;
Lehmann et al, 2018). Increased caspase-1 levels have also been
detected in serum of ALS patients (Ił _zecka et al, 2001), and analysis
of postmortem spinal cord tissue showed increased NLRP3, ASC,
caspase-1, and IL-18 expression levels, with spinal cord astrocytes
identified as the main NLRP3 inflammasome-expressing cell type
(Johann et al, 2015). However, clinical studies with anakinra in ALS
patients have not shown a significant reduction in disease progres-
sion (Maier et al, 2015), suggesting that inflammasome activation
does not play a major role in ALS, or that the pathology is driven by
IL-18 or by DAMPs via pyroptosis.
Inflammasome activation in Parkinson’s disease
Parkinson’s disease (PD) is a progressive neurodegenerative disor-
der caused by the loss of dopaminergic neurons in the substantia
nigra pars compacta. Lewy bodies are pathological hallmarks of
the disease that predominantly consist of intra-neuronal aggregates
of fibrillar a-synuclein (Przedborski, 2017). Analysis of the serum
of PD patients revealed increased levels of IL-1b and caspase-1
(Zhou et al, 2016), and elevated IL-1b levels were observed in the
striata of PD patients (Mogi et al, 1994). The midbrain of A53T
transgenic mice, which model PD based on the overexpression of
mutant human A53T a-synuclein, also contained increased IL-1b
concentrations (Zhou et al, 2016). Chronic expression of IL-1b in
the substantia nigra of rats by a recombinant adenovirus express-
ing IL-1b was shown to induce progressive death of dopaminergic
neurons and resulted in motor impairments (Ferrari et al, 2006).
However, most of the evidence linking PD to inflammasome signal-
ing comes from in vitro studies, and the importance of inflamma-
somes for the disease is not completely understood. a-Synuclein
was shown to trigger activation of the NLRP3 inflammasome in
human monocytes and BV2 microglial cells (Codolo et al, 2013;
Gustot et al, 2015; Zhou et al, 2016), but not in primary microglia
(Gustin et al, 2015). In vivo, microinjection of the caspase-1 inhi-
bitor Ac-YVAD-CMK was shown to reduce the expression of
NLRP3 inflammasome signaling proteins and improve the number
of dopaminergic neurons in LPS-induced and 6-hydroxydopamine-
induced PD in rats (Mao et al, 2017). In agreement, NLRP3 knock-
out mice were resistant to the loss of nigral dopaminergic neurons
induced by treatment with the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), which was associated with a
reduction in caspase-1 activation and IL-1b and IL-18 secretion
(Yan et al, 2015). Recently, caspase-1 was shown to cleave a-synu-
clein in vitro, generating an aggregation-prone protein that was
toxic to cultured neurons (Wang et al, 2016). Finally, mutations in
Parkin, PARK2, PARK6, and PINK1 have been identified in patients
with autosomal recessive early-onset PD, and microglia and macro-
phages from PARK2 and PINK1 knockout mice and patients with
PARK2 mutations have been shown to display an exacerbated
NLRP3 inflammasome response, possibly due to impaired expres-
sion of the anti-inflammatory protein A20 that negatively regulates
NLRP3 inflammasome activation (Mouton-Liger et al, 2018).
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Inflammasome activation in prion disease
Prion diseases are a group of rapidly progressive neurodegenerative
disorders caused by misfolded aggregated infectious prion proteins
(PrP) (Sigurdson et al, 2018). IL-1b levels are increased in the CSF
of patients with Creutzfeldt–Jakob disease (CJD) (Van Everbroeck
et al, 2002), and IL-1b and cleaved caspase-1 levels were reported
to be upregulated in the brains of scrapie-infected mice (Schultz
et al, 2004). Stimulation of microglia with an amyloidogenic PrP
peptide induced NLRP3 activation and IL-1b secretion in vitro (Shi
et al, 2012). Stimulation of microglia with PrP fibrils was also
shown to induce toxicity in neurons (Hafner-Bratkovic et al, 2012).
Mechanistically, NLRP3 inflammasome activation was suggested to
negatively regulate autophagy in microglia, thereby contributing to
neurodegeneration (Lai et al, 2018). Inhibition of IL-1R signaling
with anakinra was shown to reduce seizure susceptibility in a CJD
mouse model (Bertani et al, 2017). However, genetic ablation of
NLRP3 or ASC in mice did not affect prion pathogenesis, suggesting
that the NLRP3 inflammasome does not play a significant role in
prion disease (Nuvolone et al, 2015).
Inflammasome activation in Huntington’s disease
Huntington’s disease (HD) is an autosomal dominant progressive
neurodegenerative disease that is caused by the expansion of a trin-
ucleotide CAG repeat in the 50 coding region of the huntingtin gene,
leading to the expression of an abnormal protein that gradually
damages cells in the brain (Caron et al, 2018). Caspase-1 activation
can be detected in the brains of HD patients and in mouse models of
HD, and inhibition of caspase-1 was shown to slow down disease
progression in the R6/2 mouse model of HD (Ona et al, 1999).
Mechanistically, caspase-1 was shown to cleave mutant and wild-
type huntingtin in vitro (Wellington et al, 1998) and in vivo (Ona
et al, 1999), potentially contributing to the neurodegeneration seen
in HD. Similarly, treatment with the tetracycline derivative mino-
cycline was shown to delay disease progression by inhibition of
caspase-1 and caspase-3 expression (Chen et al, 2000).
Pharmacological targeting of inflammasomes
The central role of inflammasomes in neuroinflammatory responses,
in particular NLRP3, makes it an attractive drug target for neurode-
generative diseases. Currently approved therapies in the clinic target
the downstream effector cytokines released by inflammasome acti-
vation, such as anakinra (IL-1 receptor antagonist), canakinumab
(IL-1b neutralizing antibody), and rilonacept (soluble decoy recep-
tor for IL-1b and IL-1a) (Dinarello et al, 2012). While valuable in
treating autoinflammatory diseases (Van Gorp et al, 2019), these
IL-1 inhibitors do not prevent pyroptosis and IL-18-driven immune
activation. The need for subcutaneous administration of these
biological agents represents another drawback of these biological
agents (Moran et al, 2013; Rossi-Semerano et al, 2015), especially
in the case of anakinra, which requires daily injections due to a
short half-life of around 4–6 h (Granowitz et al, 1992). Moreover,
constitutive neutralization of IL-1b-driven signaling increases the
risk for infections, as observed in the recent CANTOS trial (Ridker
et al, 2017). Finally, the concentration of anakinra in CSF of healthy
non-human primates did not surpass 0.2–0.3% of the peripheral
serum concentration, demonstrating poor penetration of the BBB
(Fox et al, 2010). These observations urge for the development of
small molecule inflammasome antagonists with improved pharma-
cokinetic properties and efficacy, and that are able to cross the BBB.
Several small molecule inhibitors that target the inflammasome
components caspase-1, NLRP3, and GSDMD have been reported
(Table 2). Since caspase-1 activation is common to all inflamma-
some complexes, caspase-1 inhibition would serve as a pan-inflam-
masome inhibitory strategy, while compounds targeting NLRP3
have a narrower selectivity profile. Targeting the inflammasome
adaptor ASC would have an intermediate selectivity profile;
however, compounds that target ASC have not been reported to date
(Mangan et al, 2018). A number of NLRP3 inhibitory compounds
have been identified and validated in a suite of disease models
(Table 2). However, for most agents it is not known whether they
directly target NLRP3 or indirectly act on the pathway via other
mechanisms, hampering clinical development of these molecules
(Mangan et al, 2018). To date, only very few compounds targeting
NLRP3 or caspase-1 have entered clinical trials. RP-1127, an intra-
venous formulation of the NLRP3 inflammasome inhibitor glyburide
(Lamkanfi et al, 2009), is being tested in a clinical trial for stroke
(EudraCT 2017-004854-41) after a positively evaluated pilot study
(ClinicalTrials.gov: NCT01268683) (Sheth et al, 2014). RP-1127 is
also being tested in a clinical trial for TBI (ClinicalTrials.gov:
NCT01454154). In addition, the caspase-1 inhibitor VX-765 entered
a phase II clinical trial for use in epilepsy (ClinicalTrials.gov:
NCT01048255) and psoriasis (ClinicalTrials.gov: NCT00205465),
but further development has been discontinued (Mackenzie et al,
2010). The encouraging activity of small molecule NLRP3 inflamma-
some antagonists in preclinical studies warrants the development of
inflammasome-targeting therapies for clinical use.
Pyroptosis is emerging as another key mechanism that contri-
butes to inflammasome-driven pathology in metabolic, autoim-
mune, and neurodegenerative diseases. Cleavage of GSDMD by the
inflammatory caspase-1 and caspase-11 (mouse), or caspase-1,
caspase-4, and caspase-5 (human) releases an amino-terminal pore-
forming GSDMD domain that oligomerizes and inserts in the plasma
membrane, inducing membrane rupture and leakage of the cytosolic
contents (Vande Walle & Lamkanfi, 2016). Hence, GSDMD inhibi-
tion has been proposed as a novel therapeutic strategy to prevent
inflammasome-driven pathology in different diseases. Pyroptosis
has recently been shown to be the critical mechanism of IL-1b-
mediated systemic pathology in the autoinflammatory disease
Familial Mediterranean Fever (FMF), which is caused by missense
mutations in Mefv that activates the pyrin inflammasome
(Kanneganti et al, 2018). Similarly, GSDMD was shown to control
inflammasome-driven pathology in neonatal-onset multisystem
inflammatory disease (NOMID), which is caused by activating muta-
tions in the inflammasome sensor NLRP3 (Xiao et al, 2018). Indeed,
FMF knockin mice and NOMID mice were shown to be fully
protected from developing the respective autoinflammatory
syndromes when crossed into a Gsdmd-deficient background
(Kanneganti et al, 2018; Xiao et al, 2018). GSDMD was also demon-
strated to play a key role in the pathogenesis of steatohepatitis by
controlling cytokine secretion, and Gsdmd knockout mice exhibit
decreased severity of steatosis and inflammation in a high-fat
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Table 2. Overview of pharmacological compounds targeting inflammasome signaling.
Compounds Benefit (+)/detriment () Neurodegenerative disease model
Caspase-1 inhibitors
VX-765 and VX-740 () No further development after phase II clinical trial for
use in epilepsy and psoriasis (Mangan et al, 2018)
Alzheimer disease (Flores et al, 2018)
EAE (Mckenzie et al, 2018)
NLRP3 inflammasome inhibitors
Sulfonylurea-based compounds
Glyburide (+) Specific for NLRP3 inflammasomes; significantly delays
LPS-induced mortality (Lamkanfi et al, 2009)
() High dosage required (Marchetti et al, 2014);
cardiovascular side effects (Riddle, 2003)
TBI (Simard et al, 2012)
Ischemic stroke (Simard et al, 2012)
CP-412,245 and CP-424,174 (+) Oral administration of CP-424,174 selectively blocks IL-1
production in mice (Perregaux et al, 2001)
CRID1 and CRID2 () No in vivo evidence
MCC950 (also known as CRID3 or CP-456,773) (+) NLRP3 inflammasome specific (Coll et al, 2015); inhibits
NLRP3 activation by all known stimuli (Mangan et al, 2018)
() Precise molecular target unknown
Alzheimer disease (Dempsey et al, 2017)
EAE (Coll et al, 2015)
TBI (Ismael et al, 2018a; Xu et al, 2018)
Stroke (Ismael et al, 2018b; Ren et al,
2018)
16673-34-0 (+) Lacks cyclohexylurea group responsible for
hypoglycemic activity; prevents NLRP-mediated myocardial
injury (Marchetti et al, 2014)
Hybrid molecules (combining MCC950 and
glyburide)
() Moderately effective at inhibiting NLRP3 compared to
MCC950 (Hill et al, 2017)
Fenamate classes of NSAIDs
Flufenamic and mefenamic acid (+) Inhibits NLRP3 by blocking VRACs (Daniels et al, 2016)
() Lack of specificity, inhibits multiple inflammatory nodes
(Daniels et al, 2016)
Alzheimer disease (Daniels et al, 2016)
Michael acceptors
Parthenolide () No suitable pharmacological properties (Baldwin et al,
2016); inhibits NF-jB-dependent signaling (Saadane et al,
2007)
Stroke (Dong et al, 2013)
BAY 11-7082 () Not specific; inhibits NF-jB-dependent signaling (Lee
et al, 2012)
TBI (Irrera et al, 2017)
3,4-methylenedioxy-b-nitrostyrene (MNS) () Modest potency (Baldwin et al, 2016)
Acrylate and acrylamide derivatives (ex. IFN58,
IFN39)
(+) Oral administration of IFN39 alleviates DNBS-induced
colitis in rats (Cocco et al, 2017)
Novel boron compound series
NBC13 (+) Significantly decreases LPS-induced IL-1b production
in vivo (Baldwin et al, 2017)
Other NLRP3 inhibitors
Fc11a-2 (+) In vivo efficacy in DSS-induced colitis (Liu et al, 2013b)
CY-09 (+) Therapeutic effect in mouse models of CAPS and type 2
diabetes (Jiang et al, 2017)
JC-171 (+) Treatment effective in EAE in both prophylactic and
therapeutic settings (Guo et al, 2017)
EAE (Guo et al, 2017)
OLT-177 (+) No adverse effects in preliminary clinical testing of
healthy humans (Marchetti et al, 2018)
b-hydroxybutyrate (BHB) () Not specific for NLRP3; can inhibit HDACs (Youm et al,
2015)
GSDMD inhibitors
Antabuse (+) Efficacious in sepsis models (preprint: Hu et al, 2018)
Necrosulfonamide (+) Efficacious in sepsis models (Rathkey et al, 2018)
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diet-induced model of non-alcoholic steatohepatitis (Xu et al, 2017).
Pharmacologic inhibition of GSDMD by necrosulfonamide also was
efficacious in sepsis models (Rathkey et al, 2018). Finally, antabuse
(disulfiram), a drug used to treat alcohol addiction, was shown to
inhibit GSDMD pore formation and IL-1b secretion in human and
mouse cells, and LPS-induced septic death and IL-1b secretion in
mice (preprint: Hu et al, 2018). Together, these observations suggest
that inhibition of GSDMD-dependent pyroptosis may also hold
promise for the treatment of inflammasome-mediated neuroin-
flammatory pathology.
Concluding remarks and future perspectives
Although only discovered in 2002 (Martinon et al, 2002), inflamma-
somes are now widely regarded as central regulators of innate
immunity playing an indispensable role in the host defense against
stress conditions and pathogens that might be harmful to the host.
However, inflammasome activation leading to excessive or
prolonged inflammation can also contribute to a damaging and
destructive environment resulting in the development of inflamma-
tory diseases, including neurodegenerative diseases (Lamkanfi &
Dixit, 2012).
Most research in the field has focused on the role of the NLRP3
inflammasome, largely neglecting the potential importance of other
inflammasome complexes in CNS disorders. Future research will
have to investigate and characterize less well-known inflamma-
somes and expand the understanding of inflammasome signaling
and its importance for neurodegeneration. The generation of new
mouse models and reagents that allow selective targeting of the
inflammatory mechanisms initiated by these inflammasomes will be
crucial to this end. Also, although the importance of inflammasome
activation has been demonstrated in many neurodegenerative
diseases and experimental model systems, their specific role in the
different CNS cell types is not always clear. Most research has
focused on microglia, but other brain cell types also have functional
inflammasomes which may contribute to disease pathology (Walsh
et al, 2014). Since most studies published so far have investigated
inflammasome activation using conventional “full body” knockout
mice which do not allow to specify the relevant cell types involved,
cell type-specific inflammasome mutant mice will be needed to
address the importance of inflammasome signaling in CNS-specific
cell types, assessing their importance for cytokine production,
pyroptosis, and CNS inflammation. Also, new techniques including
single-cell RNA sequencing and mass cytometry, in combination
with high-resolution microscopy and in vivo cell imaging, should
help to get a better view on the spectrum of inflammasomes that is
expressed in the different CNS-resident cell types in different (patho-
logical) conditions.
Major progress needs to be made in translating findings from
animal studies to humans. However, key differences exist between
human and mouse inflammasomes. Humans have only a single
NLRP1 gene, while mice have three isoforms of Nlrp1. Similarly,
humans have two orthologues for caspase-11, viz. caspase-4 and
caspase-5 (Lamkanfi & Dixit, 2012). More research using human cell
types, eventually based on iPS technology and patient-derived mate-
rial, will be needed to translate findings more effectively from
rodents to the human conditions they model.
Finally, since inflammasome signaling is central to many
neurodegenerative diseases, targeting their activation is regarded as
a potential therapy to treat these diseases. Targeting the down-
stream IL-1b and IL-18 cytokines is probably not the best approach
since these cytokines are needed for optimal immunity in the host.
Moreover, cytokine-targeting biologics have limited capacity to
penetrate the blood–brain barrier. Therefore, modulating the activity
of specific inflammasome sensors and cell type-specific inflamma-
some targeting with small molecules will be vital in this context and
may have better potential as therapies to treat patients that suffer
from neurodegenerative diseases (Guo et al, 2015). Also, pyroptosis
is now being identified as a critical mechanism driving inflamma-
tory pathology, suggesting GSDMD inhibition as a potential anti-
inflammatory strategy (Kanneganti et al, 2018; Mckenzie et al,
2018; Xiao et al, 2018).
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Pending issues
(i) The cell type-specific contribution of inflammasome signaling to
neurodegenerative diseases, both peripheral and CNS resident.
(ii) Direct evidence for inflammasome activation and signaling in
patients with neurodegenerative disease.
(iii) Characterization of the central activation mechanism and high-
resolution structure of inflammasome proteins.
(iv) Development of compounds able to cross the BBB and that selec-
tively inhibits those inflammasomes that contribute to the
pathogenicity.
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